Amgen Commits Additional $300M to Expand Juncos Biologics Facility and Jobs
AMGN•Amgen is investing an additional $300 million in its Juncos, Puerto Rico biologics plant to scale up production, integrate new technologies and maintain uninterrupted medicine supply. This follows a prior $650 million commitment expected to generate 750 jobs and supports delivery to over 60 countries.
1. Additional $300M Investment in Juncos
Amgen plans to allocate $300 million to its Juncos, Puerto Rico biologics facility to scale production lines, integrate advanced manufacturing technologies and ensure uninterrupted supply of key therapies. This investment supplements the $650 million pledged last year and targets enhanced output for over 60 countries.
2. Job Creation and Capacity Increase
The expansion is expected to generate new construction roles, advanced manufacturing positions and support local workforce development initiatives, further extending the facility’s capacity. With the prior commitment projected to create 750 jobs, the company anticipates additional hires across technical and operational areas.
3. Broader U.S. Manufacturing Expansion
This commitment aligns with Amgen’s broader U.S. manufacturing strategy, which includes a $600 million science and innovation center in California, over $1.5 billion in North Carolina and $900 million in Ohio. The push to bolster domestic production also addresses tariff pressures on imported branded pharmaceuticals.
